Detalhe da pesquisa
1.
Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator.
Drug Metab Dispos
; 49(5): 405-419, 2021 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33674268
2.
Recurrent or progressive pediatric brain tumors: population pharmacokinetics and exposure-response analysis of pomalidomide.
Pediatr Res
; 90(4): 832-839, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-33469186
3.
Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects.
Eur J Clin Pharmacol
; 77(2): 223-231, 2021 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-32965548
4.
Neonatal Fc Receptor (FcRn) Enhances Tissue Distribution and Prevents Excretion of nab-Paclitaxel.
Mol Pharm
; 16(6): 2385-2393, 2019 06 03.
Artigo
Inglês
| MEDLINE | ID: mdl-31002261
5.
Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus.
Ann Rheum Dis
; 77(10): 1516-1523, 2018 10.
Artigo
Inglês
| MEDLINE | ID: mdl-29945920
6.
Different Nanoformulations Alter the Tissue Distribution of Paclitaxel, Which Aligns with Reported Distinct Efficacy and Safety Profiles.
Mol Pharm
; 15(10): 4505-4516, 2018 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30180593
7.
The effects of apremilast on the QTc interval in healthy male volunteers: a formal, thorough QT study.
Int J Clin Pharmacol Ther
; 54(8): 613-21, 2016 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-27285466
8.
Pharmacologic sensitivity of paclitaxel to its delivery vehicles drives distinct clinical outcomes of paclitaxel formulations.
Mol Pharm
; 12(4): 1308-17, 2015 Apr 06.
Artigo
Inglês
| MEDLINE | ID: mdl-25714793
9.
Modeling and simulation to probe the pharmacokinetic disposition of pomalidomide R- and S-enantiomers.
J Pharmacol Exp Ther
; 350(2): 265-72, 2014 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-24833703
10.
The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers.
Br J Clin Pharmacol
; 78(5): 1050-7, 2014 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-24962564
11.
Recommendation of mavacamten posology by model-based analyses in adults with obstructive hypertrophic cardiomyopathy.
CPT Pharmacometrics Syst Pharmacol
; 2024 May 02.
Artigo
Inglês
| MEDLINE | ID: mdl-38695527
12.
Effects of Omeprazole and Verapamil on the Pharmacokinetics, Safety, and Tolerability of Mavacamten: Two Drug-Drug Interaction Studies in Healthy Participants.
Clin Pharmacol Drug Dev
; 12(12): 1241-1251, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37771180
13.
Physiologically Based Pharmacokinetic Modeling and Simulation of Mavacamten Exposure with Drug-Drug Interactions from CYP Inducers and Inhibitors by CYP2C19 Phenotype.
Clin Pharmacol Ther
; 114(4): 922-932, 2023 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37467157
14.
Safety, Pharmacokinetics, and Antifibrotic Activity of CC-90001 (BMS-986360), a c-Jun N-Terminal Kinase Inhibitor, in Pulmonary Fibrosis.
Clin Pharmacol Drug Dev
; 12(8): 779-789, 2023 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-37378860
15.
Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults.
Cancer Chemother Pharmacol
; 90(4): 325-334, 2022 10.
Artigo
Inglês
| MEDLINE | ID: mdl-36001108
16.
Safety, Pharmacokinetics, and Pharmacodynamics of CC-90001 (BMS-986360), a c-Jun N-terminal Kinase Inhibitor, in Phase 1 Studies in Healthy Participants.
Clin Pharmacol Drug Dev
; 11(12): 1394-1404, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-36256505
17.
Structureâtissue exposure/selectivity relationship (STR) correlates with clinical efficacy/safety.
Acta Pharm Sin B
; 12(5): 2462-2478, 2022 May.
Artigo
Inglês
| MEDLINE | ID: mdl-35646532
18.
CC-99677, a novel, oral, selective covalent MK2 inhibitor, sustainably reduces pro-inflammatory cytokine production.
Arthritis Res Ther
; 24(1): 199, 2022 08 18.
Artigo
Inglês
| MEDLINE | ID: mdl-35982464
19.
Concentration-QTc Modeling of Ozanimod's Major Active Metabolites in Adult Healthy Subjects.
CPT Pharmacometrics Syst Pharmacol
; 10(2): 119-126, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33314790
20.
Population Pharmacokinetics and Exposure-Response Analysis of nab-Paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors.
Clin Pharmacol Drug Dev
; 10(2): 115-130, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-32459889